GSK Financial Analysis
GSK Key Indicators
GSK Income Statement
GSK Balance Sheet
GSK Cash Flow
Quarterly
| FY2024Q4 | FY2024Q3 | FY2024Q2 | FY2024Q1 | FY2023Q4 | FY2023Q3 | FY2023Q2 | FY2023Q1 | FY2022Q4 | FY2022Q3 | FY2022Q2 | FY2022Q1 | FY2021Q4 | FY2021Q3 | FY2021Q2 | FY2021Q1 | FY2020Q4 | FY2020Q3 | FY2020Q2 | FY2020Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Assets | 74.39B -0.95% | 77.61B 4.55% | 73.41B -2.82% | 73.86B 2.20% | 75.11B 3.23% | 74.23B 10.29% | 75.54B -30.32% | 72.27B -38.65% | 72.76B -32.01% | 67.31B -36.51% | 108.41B 1.81% | 117.79B 9.48% | 107.02B -2.69% | 106.01B 1.42% | 106.48B 1.47% | 107.59B 2.67% | 109.97B 4.08% | 104.53B 2.19% | 104.94B 29.93% | 104.79B |
Total Current Assets | 21.26B -10.40% | 23.13B -10.73% | 21.19B -13.78% | 21.72B -10.70% | 23.73B -5.54% | 25.91B 14.64% | 24.58B -62.74% | 24.32B -36.12% | 25.12B -0.55% | 22.60B -8.11% | 65.97B 171.62% | 38.07B 49.15% | 25.26B -8.74% | 24.59B -4.23% | 24.29B -14.75% | 25.52B -6.67% | 27.68B 7.12% | 25.68B -0.43% | 28.49B 23.14% | 27.35B |
Total Non-Current Assets | 53.13B 3.41% | 54.48B 12.74% | 52.21B 2.46% | 52.14B 8.75% | 51.38B 7.85% | 48.33B 8.09% | 50.96B 20.08% | 47.95B -39.85% | 47.63B -41.73% | 44.71B -45.08% | 42.44B -48.37% | 79.72B -2.85% | 81.75B -0.65% | 81.42B 3.26% | 82.19B 7.51% | 82.06B 5.97% | 82.29B 3.09% | 78.85B 3.08% | 76.45B 32.66% | 77.44B |
Total Liabilities | 58.02B -1.36% | 59.63B 1.33% | 56.00B -6.81% | 57.16B -1.98% | 58.82B -2.85% | 58.84B 2.19% | 60.09B -25.67% | 58.32B -33.78% | 60.55B -22.52% | 57.58B -24.94% | 80.85B 5.48% | 88.07B 11.99% | 78.15B -4.14% | 76.71B -1.51% | 76.65B -4.16% | 78.64B -1.50% | 81.52B 0.24% | 77.89B -2.75% | 79.98B 3.86% | 79.83B |
Total Current Liabilities | 27.15B 1.22% | 28.69B 5.06% | 25.72B -8.42% | 25.05B -1.85% | 26.82B -2.81% | 27.31B 16.79% | 28.09B -39.03% | 25.52B -19.95% | 27.59B -13.83% | 23.38B -22.57% | 46.06B 55.77% | 31.88B 14.13% | 32.02B 5.75% | 30.20B 5.42% | 29.57B -0.31% | 27.94B -11.20% | 30.28B -5.03% | 28.65B -8.62% | 29.66B -9.35% | 31.46B |
Total Non-Current Liabilities | 30.88B -3.52% | 30.93B -1.90% | 30.28B -5.40% | 32.11B -2.08% | 32.00B -2.88% | 31.53B -7.79% | 32.01B -7.98% | 32.79B -41.63% | 32.95B -28.55% | 34.20B -26.47% | 34.78B -26.11% | 56.18B 10.82% | 46.12B -9.99% | 46.51B -5.54% | 47.08B -6.44% | 50.70B 4.82% | 51.24B 3.65% | 49.24B 1.02% | 50.31B 13.62% | 48.37B |
Total Shareholders' Equity | 16.37B 0.52% | 17.99B 16.86% | 17.41B 12.70% | 16.70B 19.70% | 16.29B 33.35% | 15.39B 58.23% | 15.45B -43.96% | 13.95B -53.06% | 12.21B -57.70% | 9.73B -66.80% | 27.56B -7.61% | 29.72B 2.67% | 28.87B 1.49% | 29.30B 9.98% | 29.84B 19.50% | 28.95B 16.00% | 28.45B 16.89% | 26.64B 20.05% | 24.97B 562.98% | 24.96B |
Shareholders' Equity | 17.10B 0.67% | 18.73B 16.92% | 18.17B 12.69% | 17.47B 19.84% | 16.99B 32.52% | 16.02B 56.83% | 16.12B -19.12% | 14.58B -31.40% | 12.82B -37.06% | 10.21B -50.85% | 19.94B -6.24% | 21.25B 3.75% | 20.37B 2.12% | 20.78B 12.63% | 21.26B 26.15% | 20.48B 25.97% | 19.94B 31.89% | 18.45B 27.57% | 16.85B 267.41% | 16.26B |
Minority Interest | -731.89M 4.16% | -742.04M 18.36% | -761.05M 12.61% | -771.27M 23.10% | -702.64M 15.70% | -626.93M 28.85% | -675.86M -108.86% | -626.52M -107.40% | -607.27M -107.14% | -486.57M -105.71% | 7.63B -11.03% | 8.47B 0.06% | 8.51B -0.00% | 8.52B 4.02% | 8.57B 5.67% | 8.47B -2.63% | 8.51B -7.72% | 8.19B 5.97% | 8.11B -1088.01% | 8.70B |
Total Liabilities & Equity | 74.39B -0.95% | 77.61B 4.55% | 73.41B -2.82% | 73.86B 2.20% | 75.11B 3.23% | 74.23B 10.29% | 75.54B -30.32% | 72.27B -38.65% | 72.76B -32.01% | 67.31B -36.51% | 108.41B 1.81% | 117.79B 9.48% | 107.02B -2.69% | 106.01B 1.42% | 106.48B 1.47% | 107.59B 2.67% | 109.97B 4.08% | 104.53B 2.19% | 104.94B 29.93% | 104.79B |
Net Debt | 16.38B 0.27% | 17.18B -0.50% | 17.65B -7.20% | 17.26B 0.49% | 16.34B 3.02% | 17.26B 3.44% | 19.02B 0.27% | 17.18B -32.40% | 15.86B -40.91% | 16.69B -43.92% | 18.97B -37.42% | 25.41B -13.82% | 26.84B -5.54% | 29.76B -3.52% | 30.31B 4.30% | 29.49B -12.53% | 28.41B -16.69% | 30.85B -12.40% | 29.06B -21.74% | 33.72B |
Working Capital | -5.88B 90.57% | -5.56B 296.62% | -4.53B 29.11% | -3.33B 176.67% | -3.09B 24.97% | -1.40B 78.53% | -3.51B -117.61% | -1.20B -119.48% | -2.47B -63.47% | -785.66M -85.99% | 19.91B -476.84% | 6.19B -356.38% | -6.76B 160.04% | -5.61B 88.96% | -5.28B 350.43% | -2.41B -41.34% | -2.60B -57.00% | -2.97B -46.60% | -1.17B -87.76% | -4.11B |
Free Financial AI Agent for Investment
Ask any investment related question and get answer instantly
Is GSK earnings result positive or negative?How should I trade on GSK earnings?GSK FAQs
What is GSK's PE Ratio in 2025/4/4?
GSK's PE ratio in April 4, 2025 is 22.79. This indicates the price investors are willing to pay for $1 of earnings.
What is GSK's PS Ratio in 2025/4/4?
GSK's PS ratio in April 4, 2025 is 1.84. This indicates how much investors are willing to pay for each dollar of the company's sales.
What is GSK's Dividend Yield in 2024/Q4?
GSK's Dividend Yield in 2024/Q4 is 4.52%. This represents the return on investment from dividends relative to the stock price.
What is GSK's Gross Margin in 2024/Q4?
GSK's Gross Margin in 2024/Q4 is 68.93. Gross Margin is typically calculated as (Revenue - Cost of Goods Sold) / Revenue and is a key indicator of a company's financial health and efficiency in managing production costs.
Free Financial AI Agent for Investment
Ask any investment related question and get answer instantly
Is GSK earnings result positive or negative?How should I trade on GSK earnings?